Published on
Last updated on
New Details on Sampling Inspections of Medical Devices
On April 12, the NMPA (National Medical Products Administration) announced (No.45-2021) the inspection plan for medical devices. For foreign manufacturers, this is most relevant for post-market activities and will be useful when manufacturers are notified for sampling inspections by the NMPA.
Highlights
- The inspection work shall be carried out in accordance with the mandatory standards or product technical requirements as indicated in the item list (attached in the NMPA announcement).
- If the medical device manufacturer objects to the inspection results, he can apply for re-inspection within 7 working days from the date of receiving the results. The medical device manufacturer should refer to the list of inspection companies (attached in the NMPA announcement) to apply for re-inspection.
- If the medical device manufacturer objects the test method and test basis and at the same time fails the re-inspection, he can apply for an appeal with the respective MPA within 10 working days from the date of receiving the results. Upon receiving the application, the MPA will investigate and submit a proposal report to the NIFDC (National Institutes for Food and Drug Control).
By Jacky Li. Contact Cisema if you would like to learn more.
Related News
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.